Effect of Rosuvastatin on fasting plasma glucose after coronary stent implantation in elderly patients

Objective To investigate the effect of Rosuvastatin on fasting plasma glucose after coronary stent implantation in elderly patients with non-diabetes mellitus. Methods A total of 216 non-diabetic elderly patients undergoing coronary stent implantation in our hospital from November 2015 to April 2018 were enrolled, with a follow-up in the cardiovascular department after discharge from the Hospital.The demographic data, follow-up time, and laboratory results at hospital admission and the last outpatient visit were collected retrospectively. Results At the end of follow-up, Fasting plasma glucose(FPG)was increased in 191 patients with normal baseline FPG level as compared with the baseline level(t=-3.783, P=0.000). The incidence of new-onset diabetes was higher in the pre-diabetes group than in the normal blood glucose group(24.0% vs.2.6%, χ2=16.72, P=0.000). Conclusions Rosuvastatin increases fasting blood glucose levels in elderly non-diabetic patients after coronary stent implantation.Pre-diabetes may increase the risk for rosuvastatin-associated new-onset diabetes. Key words: Coronary artery disease; Blood glucose